DK1701738T3 - Fremgangsmåde til fremstilling af lagringsstabile RSV-sammensætninger - Google Patents
Fremgangsmåde til fremstilling af lagringsstabile RSV-sammensætninger Download PDFInfo
- Publication number
- DK1701738T3 DK1701738T3 DK04814040.4T DK04814040T DK1701738T3 DK 1701738 T3 DK1701738 T3 DK 1701738T3 DK 04814040 T DK04814040 T DK 04814040T DK 1701738 T3 DK1701738 T3 DK 1701738T3
- Authority
- DK
- Denmark
- Prior art keywords
- approx
- temperature
- minutes
- virus
- virus composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18651—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Claims (20)
1. Fremgangsmåde til minimering af RSV-styrketab under lyofiliseringen og til fremstilling af en lagringsstabil virussammensætning omfattende respiratorisk syncytialvirus (RSV), hvilken fremgangsmåde omfatter: (a) nedfrysning af en virussammensætning fra mellem ca. 100 μΙ til ca. 5 ml_ under sin glasovergangstemperatur i en periode på 60 minutter eller mindre ved en rate fra -0,5 °C til -2,5 °C per minut, hvorved virussammensætningen formuleres i en 5,0 mM til ca. 20 mM phosphatbufferopløsning omfattende monobasisk og dibasisk natrium- og/eller kaliumsalt og med pH fra ca. 6,5 til ca. 7,8; og (B) lyofilisering af virussammensætningen, hvor den lyofiliserede virussammensætning er stabil i mindst et år ved en lagringstemperatur fra ca. 1 °C til ca. 10 °C.
2. Fremgangsmåde ifølge krav 1, hvorved glasovergangstemperaturen er ca. -40 °C til ca. -50 °C.
3. Fremgangsmåde ifølge krav 1, hvorved glasovergangstemperaturen er ca. -30 °C til ca. -40 °C.
4. Fremgangsmåde ifølge krav 3, hvorved glasovergangstemperaturen på ca. -35 °C opnås i en periode på 40 minutter eller mindre.
5. Fremgangsmåde ifølge krav 3, hvorved glasovergangstemperaturen på ca. -35 °C opnås i en periode på 20 minutter eller mindre.
6. Fremgangsmåde ifølge krav 5, hvorved virussammensætningen formuleres i en 10 mM phosphatbufferopløsning omfattende monobasisk og dibasisk natrium- og/eller kaliumsalt og med pH fra ca. 6,5 til ca. 7,8.
7. Fremgangsmåde ifølge krav 6, hvorved virussammensætningen desuden omfatter ca. 0,25 mM til ca. 25 mM N-2-hydroxyethylpiperazin-N'-2-ethanesulfonsyre (HEPES).
8. Fremgangsmåde ifølge krav 6, hvorved virussammensætningen desuden omfatter ca. 0,01 mM til ca. 1 mM magnesiumchlorid og ca. 0,01 mM til ca. 1 mM calciumchlorid.
9. Fremgangsmåde ifølge krav 6, hvorved virussammensætningen desuden omfatter ca. 0,25 mM til ca. 25 mM HEPES, ca. 0,01 mM til ca. 1 mM mag-nesiumchlorid og ca. 0,01 mM til ca. 1 mM calciumchlorid.
10. Fremgangsmåde ifølge krav 9, hvorved virussammensætningen desuden omfatter sakkarose, L(+)-glutaminsyre eller L(+)- glutaminsyremononatriumsalt eller en blanding af L(+)-glutaminsyre/L(+)-glutaminsyremononatriumsalt og humant albumin (HA).
11. Fremgangsmåde ifølge krav 10, hvorved HA er nativt eller rekombinant.
12. Fremgangsmåde ifølge krav 10, hvorved virussammensætningen desuden omfatter sojapepton.
13. Fremgangsmåde ifølge krav 10, hvorved virussammensætningen desuden omfatter ca. 50 g/L sakkarose, ca. 0,049 mM til ca. 2,45 mM L(+)-glutaminsyre eller ca. 0,049 mM til ca. 2,45 mM L(+)-glutaminsyremononatriumsalt eller en blanding deraf og ca. 1,0 g/L til ca. 10,0 g/L HA.
14. Fremgangsmåde ifølge krav 13, hvorved ca. 1,0 g/L til ca. 10,0 g/L HA substitueres med ca. 50 g/L sojapepton.
15. Fremgangsmåde ifølge krav 12, hvorved virussammensætningen omfatter ca. 50 g/L sakkarose, ca. 0,049 mM til ca. 2,45 mM L(+)-glutaminsyre eller ca. 0,049 mM til ca. 2,45 mM L(+)-glutaminsyremononatriumsalt eller en blanding deraf, ca. 1,0 g/L til ca. 10 g/L HA og ca. 50 g/L sojapepton.
16. Fremgangsmåde ifølge krav 1, hvorved lagringstemperaturen er 5 °C.
17. Fremgangsmåde ifølge krav 1, hvorved lyofilisering af virussammensætningen i trin (b) omfatter ca. 0,2 mL til ca. 1,0 mL af virussammensætningen i et egnet beholdermiddel.
18. Fremgangsmåde ifølge krav 17, hvorved et beholdermiddel endvidere er defineret som et hætteglas, et rør eller en næsesprayindretning.
19. Fremgangsmåde ifølge krav 1, endvidere defineret som: (a) anbringelse af ca. 0,5 ml_ til ca. 0,6 ml_ af virussammensætningen i et hætteglas og nedkøling til en temperatur på ca. 5 °C; (b) anbringelse af hætteglasset på en lyofiliseringshylde og reducering af hyldetemperaturen fra 5 °C til -50 °C ved en rate fra ca. -1,0 °C per minut til ca. -2,0 °C per minut; (c) fastholdelse af hyldetemperaturen ved ca. -50 °C i 60 minutter; (d) reducering af kammertrykket til 13,33 Pa (0,10 Torr) og fastholdelse af hyldetemperaturen ved ca. -50 °C i 30-60 minutter; (e) forøgelse af hyldetemperaturen fra -50 °C til 0 °C ved en rate fra ca. 1,0 °C per minut til ca. 2,0 °C ved ca. 13,33 Pa (ca. 0,10 Torr) og fastholdelse af hyldetemperaturen ved ca. 0 °C i ca. 540 minutter til ca. 720 minutter; (f) forøgelse af hyldetemperaturen fra 0 °C til 15 °C ved en rate på ca. 0,5 °C per minut ved ca. 13,33 Pa (ca. 0,10 Torr) og fastholdelse af hyldetemperaturen ved ca. 15 °C i ca. 600 minutter til ca. 720 minutter og (g) fyldning af hætteglasset med nitrogengas og hermetisk forsegling af hætteglasset.
20. Fremgangsmåde ifølge krav 1, endvidere defineret som: (a) anbringelse af ca. 0,5 ml_ til ca. 0,6 mL af virussammensætningen i et hætteglas og nedkøling til en temperatur på ca. 5 °C; (b) nedfrysning af en lyofiliseringshylde til en temperatur på ca. -70 °C; (c) anbringelse af hætteglasset på lyofiliseringshylden og fastholdelse af temperaturen ved ca. -70 °C i ca. 60 minutter; (d) reducering af kammertrykket til ca. 13,33 Pa (ca. 0,10 Torr) og forøgelse af hyldetemperaturen fra-70 °C til -50 °C ved en rate på ca. 1,0 °C per minut; (e) forøgelse af hyldetemperaturen fra -50 °C til 0 °C ved en rate fra ca. 1,0 °C per minut til ca. 2,0 °C per minut ved ca. 13,33 Pa (ca. 0,10 Torr) og fastholdelse af hyldetemperaturen ved ca. 0 °C i ca. 540 minutter til ca. 720 minutter; (f) forøgelse af hyldetemperaturen fra 0 °C til 15 °C ved en rate på ca. 0,5 °C per minut ved ca. 13,33 Pa (ca. 0,10 Torr) og fastholdelse af hyldetemperaturen ved ca. 15 °C i ca. 600 minutter til ca. 720 minutter og (g) fyldning af hætteglasset med nitrogengas og hermetisk forsegling af hætteglasset.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53032503P | 2003-12-17 | 2003-12-17 | |
PCT/US2004/041803 WO2005058356A2 (en) | 2003-12-17 | 2004-12-10 | Methods for porducing storage stable viruses and immunogenic compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1701738T3 true DK1701738T3 (da) | 2015-03-30 |
Family
ID=34700123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04814040.4T DK1701738T3 (da) | 2003-12-17 | 2004-12-10 | Fremgangsmåde til fremstilling af lagringsstabile RSV-sammensætninger |
Country Status (13)
Country | Link |
---|---|
US (1) | US8603796B2 (da) |
EP (1) | EP1701738B1 (da) |
JP (1) | JP4691509B2 (da) |
CN (1) | CN1893973B (da) |
AR (1) | AR046900A1 (da) |
AU (1) | AU2004299057B2 (da) |
BR (1) | BRPI0417672A (da) |
CA (1) | CA2549197C (da) |
DK (1) | DK1701738T3 (da) |
ES (1) | ES2536322T3 (da) |
IL (1) | IL176109A0 (da) |
MX (1) | MXPA06006947A (da) |
WO (1) | WO2005058356A2 (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2458125C2 (ru) * | 2004-11-05 | 2012-08-10 | Веллстат Байолоджикс Корпорейшн | Способ стабилизации вируса ньюкаслской болезни для хранения в водном растворе и способ сохранения его стабильности |
PL1942932T3 (pl) * | 2005-08-08 | 2013-11-29 | Univ Oregon Health & Science | Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek |
RS51996B (en) * | 2005-09-16 | 2012-04-30 | Merial Ltd. | Freeze dried vaccine stabilizers |
CN101489587B (zh) * | 2006-05-12 | 2015-05-27 | 伯哈拉特生物技术国际有限公司 | 一种可用作疫苗的组合物 |
GB0614460D0 (en) * | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
DE102007023198A1 (de) * | 2007-05-18 | 2008-11-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Magazin für zylindrische Gefässe |
MY162326A (en) * | 2009-07-13 | 2017-05-31 | Bharat Biotech Int Ltd | A composition useful as rotavirus vaccine and a method therefor |
EP2689785B1 (en) * | 2010-04-15 | 2021-05-19 | Shin Nippon Biomedical Laboratories, Ltd. | Method for generating dry vaccine powder formulation for inranasal delivery |
CN104147605A (zh) * | 2010-08-13 | 2014-11-19 | 高级生物营养公司 | 用于生物材料的干的贮存稳定用组合物及其制备方法 |
JP6034797B2 (ja) | 2010-12-02 | 2016-11-30 | オンコリティクス バイオテク,インコーポレーテッド | 凍結乾燥されたウイルス製剤 |
AU2011336413B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
US8771402B2 (en) * | 2011-06-14 | 2014-07-08 | Ut-Battelle, Llc | Membrane based apparatus for measurement of volatile particles |
EP2741740B1 (en) | 2011-08-12 | 2017-05-03 | Merial, Inc. | Vacuum-assisted preservation of biological products, in particular of vaccines |
WO2013040196A2 (en) | 2011-09-14 | 2013-03-21 | Immunovative Therapies, Ltd. | Automated device for biologic drug distribution |
CN104271119B (zh) | 2012-03-05 | 2018-07-10 | 由卫生福利和体育大臣代表的荷兰王国 | 用于稳定干燥的生物材料的方法和组合物 |
CN102813933A (zh) * | 2012-08-30 | 2012-12-12 | 青岛康地恩药业股份有限公司 | 鸡传染性法氏囊病卵黄抗体冻干保护剂 |
TWI610861B (zh) * | 2012-09-13 | 2018-01-11 | 梵提夫免疫療法公司 | 用於生物藥品分配的自動化裝置 |
TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
SG11201507462QA (en) | 2013-03-14 | 2015-10-29 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
BR112020008482A8 (pt) * | 2017-11-01 | 2023-01-31 | Merck Sharp & Dohme | Composto leuco |
CN110938603B (zh) * | 2019-12-20 | 2022-11-22 | 阿吉安(福州)基因医学检验实验室有限公司 | 一种通用型病毒样本保存缓冲液及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4084330A (en) * | 1976-07-02 | 1978-04-18 | Fts Systems, Inc. | Flask for freeze drying with adjustable seal |
US4273762A (en) * | 1979-12-03 | 1981-06-16 | Merck & Co., Inc. | Lyophilization process for live viral compositions |
IL105456A (en) * | 1992-04-21 | 1996-12-05 | American Home Prod | Vaccines of attenuated respiratory syncytial virus |
TW275632B (da) * | 1992-04-21 | 1996-05-11 | American Cyanamid Co | |
US5489266A (en) * | 1994-01-25 | 1996-02-06 | Becton, Dickinson And Company | Syringe assembly and method for lyophilizing and reconstituting injectable medication |
JPH10503993A (ja) * | 1994-08-19 | 1998-04-14 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | 凍結乾燥用のベント式バイアルと凍結乾燥された生産品の汚染を最少限にする方法 |
US6077514A (en) * | 1996-04-04 | 2000-06-20 | The Regents Of The University Of Michigan | Attenuated respiratory syncytial virus |
JP4413999B2 (ja) * | 1996-07-15 | 2010-02-10 | アメリカ合衆国 | クローニングされたヌクレオチド配列からの弱毒化呼吸シンシチウムウィルスワクチンの製造 |
US6290967B1 (en) * | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
US6410023B1 (en) * | 1997-05-23 | 2002-06-25 | United States Of America | Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
US20040022800A1 (en) * | 2000-07-31 | 2004-02-05 | Mark Parrington | Respiratory syncytial virus vaccine |
GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
WO2003086443A1 (en) * | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
BR0313806A (pt) | 2002-08-26 | 2005-07-05 | Pfizer Prod Inc | Vacinas para infecções nos sistemas respiratório e reprodutor em gado |
-
2004
- 2004-12-10 CA CA2549197A patent/CA2549197C/en not_active Expired - Fee Related
- 2004-12-10 BR BRPI0417672-3A patent/BRPI0417672A/pt not_active Application Discontinuation
- 2004-12-10 DK DK04814040.4T patent/DK1701738T3/da active
- 2004-12-10 EP EP04814040.4A patent/EP1701738B1/en active Active
- 2004-12-10 JP JP2006545794A patent/JP4691509B2/ja not_active Expired - Fee Related
- 2004-12-10 AU AU2004299057A patent/AU2004299057B2/en not_active Ceased
- 2004-12-10 US US10/582,461 patent/US8603796B2/en not_active Expired - Fee Related
- 2004-12-10 CN CN2004800377252A patent/CN1893973B/zh not_active Expired - Fee Related
- 2004-12-10 ES ES04814040.4T patent/ES2536322T3/es active Active
- 2004-12-10 MX MXPA06006947A patent/MXPA06006947A/es active IP Right Grant
- 2004-12-10 WO PCT/US2004/041803 patent/WO2005058356A2/en active Application Filing
- 2004-12-16 AR ARP040104693A patent/AR046900A1/es unknown
-
2006
- 2006-06-04 IL IL176109A patent/IL176109A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2549197C (en) | 2015-04-14 |
CA2549197A1 (en) | 2005-06-30 |
AU2004299057A1 (en) | 2005-06-30 |
US8603796B2 (en) | 2013-12-10 |
ES2536322T3 (es) | 2015-05-22 |
IL176109A0 (en) | 2006-10-05 |
WO2005058356A2 (en) | 2005-06-30 |
CN1893973B (zh) | 2010-12-08 |
EP1701738A2 (en) | 2006-09-20 |
WO2005058356A3 (en) | 2005-11-17 |
AU2004299057B2 (en) | 2010-06-24 |
AR046900A1 (es) | 2005-12-28 |
MXPA06006947A (es) | 2007-01-26 |
US20080206281A1 (en) | 2008-08-28 |
EP1701738B1 (en) | 2015-03-11 |
JP2007514450A (ja) | 2007-06-07 |
BRPI0417672A (pt) | 2007-03-20 |
JP4691509B2 (ja) | 2011-06-01 |
CN1893973A (zh) | 2007-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1701738T3 (da) | Fremgangsmåde til fremstilling af lagringsstabile RSV-sammensætninger | |
US8142795B2 (en) | Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses | |
AU2009200127B2 (en) | Preservation of bioactive materials by freeze dried foam | |
US7923029B2 (en) | Spray freeze dry of compositions for pulmonary administration | |
US20040042972A1 (en) | Spray freeze dry of compositions for intranasal administration | |
US20110177119A1 (en) | Stable, dried rotavirus vaccine, compositions and process for preparation thereof | |
US20110243988A1 (en) | Methods and Compositions for Stabilization of a Virus Vaccine | |
CA2873775C (en) | Herpesvirus compositions and related methods | |
KR101168458B1 (ko) | 저장 안정성 바이러스 및 이의 면역원성 조성물의 제조방법 | |
Asim et al. | Effect of various stabilizers on titre of lyophilized live-attenuated Peste des petits ruminants (PPR) vaccine. |